Neurocrine Biosciences (NBIX) Net Cash Flow Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -1,020.00% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 383.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,047.81% |
| Dec 31, 2025 | 421.93% |
| Sep 30, 2025 | -63.46% |
| Jun 30, 2025 | 127.16% |
| Mar 31, 2025 | -126.79% |
| Dec 31, 2024 | -169.93% |
| Sep 30, 2024 | 56.63% |
| Jun 30, 2024 | -553.36% |
| Mar 31, 2024 | 191.26% |
| Dec 31, 2023 | -182.50% |
| Sep 30, 2023 | 173.01% |
| Jun 30, 2023 | 152.95% |
| Mar 31, 2023 | -141.06% |
| Dec 31, 2022 | 75.08% |
| Sep 30, 2022 | 185.94% |
| Jun 30, 2022 | -794.16% |
| Mar 31, 2022 | -139.88% |
| Dec 31, 2021 | 112.47% |
| Sep 30, 2021 | -657.84% |
| Jun 30, 2021 | -93.25% |